Conditions: Acute Myelogenous Leukemia
Keywords: Phase I Phase II acute myelogenous leukemia AML cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 47
Healthy volunteers: no

Brief summary:
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a daily times 3 schedule in acute myelogenous leukemia (AML).

For enrollment information see the Central Contact information below

Detailed description:

Arms:

Interventions: intervention 1: AZD4877
Intervention descriptions: intervention 1: intravenous infusion administered on days 1, 2 and 3

Protocol document: